Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
CRISPR Therapeutics AG - Common Shares
(NQ:
CRSP
)
56.18
+56.17 (+1003114.29%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about CRISPR Therapeutics AG - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
...
36
37
Next >
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
↗
Today 12:31 EDT
One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.
Via
The Motley Fool
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?
↗
May 25, 2026
Are there significant gains ahead for one (or both) of these innovative biotechs?
Via
The Motley Fool
The Best Stocks to Invest $3,000 In Right Now
↗
May 19, 2026
Not every high-potential name costs a fortune to step into.
Via
The Motley Fool
CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms
↗
May 15, 2026
CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple...
Via
MarketBeat
Topics
Intellectual Property
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?
↗
May 11, 2026
The biotech's innovative platform could pay off.
Via
The Motley Fool
Is This Millionaire-Maker Biotech Stock a Buy Right Now?
↗
May 06, 2026
The market wasn't impressed by its latest quarterly update.
Via
The Motley Fool
Topics
Initial Public Offering
Want to Build Real Wealth in Healthcare? These Stocks Are Worth Considering
↗
April 30, 2026
These companies are leaders in their fields.
Via
The Motley Fool
What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer.
↗
April 30, 2026
The biotech's candidate may treat a great number of illnesses that have one thing in common.
Via
The Motley Fool
Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead?
↗
April 30, 2026
This particular player has seen its yield rise in recent years.
Via
The Motley Fool
3 Growth Stocks That Could Generate 10X Returns
↗
April 29, 2026
These stocks come with risk, but they also have some exciting long-term growth opportunities.
Via
The Motley Fool
Topics
Cannabis
Law Enforcement
3 Biotech Stocks That Could Benefit from the Patent Cliff
↗
April 27, 2026
Via
MarketBeat
Topics
Intellectual Property
CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy?
↗
April 21, 2026
We'll know more about the company's medium-term prospects by the end of the year.
Via
The Motley Fool
2 Billion Reasons to Love CRISPR Therapeutics Right Now
↗
April 13, 2026
The company's strong cash position gives investors confidence in the gene-editing stock.
Via
The Motley Fool
This Biotech Has a Pipeline That Could Redefine Its Entire Therapeutic Area
↗
April 08, 2026
Innovation often pays off, and this biotech could cement its innovative capabilities in the next few years.
Via
The Motley Fool
Is This Biotech Stock Your Best Shot at Building a Millionaire-Making Position?
↗
April 07, 2026
With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has attracted a big Investor.
Via
The Motley Fool
Topics
ETFs
CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now?
↗
March 23, 2026
The gene-editing stock has been in a tailspin of late.
Via
The Motley Fool
Vertex Pharmaceuticals (VRTX): The Evolution of a Biotech Powerhouse in 2026
March 20, 2026
As of March 20, 2026, Vertex Pharmaceuticals (NASDAQ: VRTX) has officially transcended its long-held identity as "the cystic fibrosis (CF) company." For over a decade, the Boston-based biotech giant...
Via
Finterra
Topics
Intellectual Property
Is CRISPR Therapeutics Stock a Buy Now?
↗
March 20, 2026
We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.
Via
The Motley Fool
3 Monster Stocks to Hold for the Next 10 Years
↗
March 10, 2026
They're names worth holding for far longer, but the coming decade could prove particularly fruitful for these companies.
Via
The Motley Fool
Topics
Artificial Intelligence
This Is Why CRISPR Therapeutics Stock Is Tumbling on Tuesday
↗
March 10, 2026
Current shareholders were thrown an unexpected curveball that they actually should have been expecting.
Via
The Motley Fool
Why Is CRSP Stock Falling Pre-Market Today?
↗
March 10, 2026
The company plans to issue $350 million in convertible senior notes that are scheduled to mature in 2031.
Via
Stocktwits
RIVN Stock Gains 4% Pre-Market After TD Cowen Upgrade: Analyst Sees Strong Demand For Upcoming R2 Models
↗
March 10, 2026
The firm believes the new lineup could significantly expand Rivian's addressable EV market.
Via
Stocktwits
Topics
Electric Vehicles
Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of
↗
March 04, 2026
These two biotechs have a lot in common. Their differences are even more pronounced.
Via
The Motley Fool
Is CRISPR Therapeutics Stock Too Risky to Buy Right Now?
↗
March 02, 2026
CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential.
Via
The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
↗
March 01, 2026
Could these three stocks be Cathie Wood's next big winners?
Via
The Motley Fool
Topics
ETFs
Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off?
↗
February 20, 2026
The past few years have been challenging for the biotech.
Via
The Motley Fool
The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices
↗
February 20, 2026
Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.
Via
The Motley Fool
Topics
ETFs
2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street
↗
February 19, 2026
These biotech companies have catalysts ahead.
Via
The Motley Fool
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows
↗
February 19, 2026
Via
MarketBeat
Should You Buy Shares of CRISPR Therapeutics in February?
↗
February 18, 2026
The company could finally be ready to deliver on years of promise.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
36
37
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
